Incretin Atlas › Trials › SURMOUNT-1
SURMOUNT-1
Tirzepatide · obesity
Design
- Molecule(s)
- Tirzepatide
- Population
- obesity
- Official title
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
- Sponsor
- Eli Lilly and Company
- Phase
- 3
- Registry status
- completed · 2019-12 → 2022-04
- Participants
- 2539
- Duration
- 72 weeks
- Registry
- NCT04184622, NCT07481747
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| tirzepatide 5 mg | obesity | 72 | 2539 | −16.0 % vs −2.4 % Δ −13.6 pp | −15.0 % vs −3.1 % Δ −11.9 pp | — | 4.3 vs 2.6 | — | 24.6 vs 9.5 | 8.3 vs 1.7 | 6.3 vs 6.8 | — | verified |
| tirzepatide 10 mg | obesity | 72 | 2539 | −21.4 % vs −2.4 % Δ −19.0 pp | −19.5 % vs −3.1 % Δ −16.4 pp | — | 7.1 vs 2.6 | — | 33.3 vs 9.5 | 10.7 vs 1.7 | 6.9 vs 6.8 | — | verified |
| tirzepatide 15 mg | obesity | 72 | 2539 | −22.5 % vs −2.4 % Δ −20.1 pp | −20.9 % vs −3.1 % Δ −17.8 pp | — | 6.2 vs 2.6 | — | 31.0 vs 9.5 | 12.2 vs 1.7 | 5.1 vs 6.8 | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- tirzepatide 5 mg: Per-arm discontinuation of the study drug is printed only as a range across doses.
- tirzepatide 10 mg: Per-arm discontinuation of the study drug is printed only as a range across doses.
- tirzepatide 15 mg: Per-arm discontinuation of the study drug is printed only as a range across doses.
Verbatim quotes from the source (18)
- tirzepatide 5 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Fig. 1B
−16.0% (95% CI, −16.8 to −15.2), a weight reduction of 16.1 kg (35.5 lb), with the 5-mg dose
- tirzepatide 5 mg · weight_tp · Results, Change in Body Weight, paragraph 1; Table 2
−15.0% (95% CI, −15.9 to −14.2) with a 5-mg weekly dose of tirzepatide
- tirzepatide 5 mg · ae_dc · Results, Participants; Table 4 (27 [4.3])
Treatment discontinuations due to adverse events were 4.3%, 7.1%, and 6.2% with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 2.6% with placebo.
- tirzepatide 5 mg · nausea · Table 4, adverse events in at least 5% of participants
Nausea 155 (24.6) 212 (33.3) 195 (31.0) 61 (9.5)
- tirzepatide 5 mg · vomiting · Table 4, adverse events in at least 5% of participants
Vomiting 52 (8.3) 68 (10.7) 77 (12.2) 11 (1.7)
- tirzepatide 5 mg · sae · Table 4
Serious adverse events 40 (6.3) 44 (6.9) 32 (5.1) 44 (6.8)
- tirzepatide 10 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Fig. 1B
−21.4% (95% CI, −22.2 to −20.6), a reduction of 22.2 kg (48.9 lb), with the 10-mg dose
- tirzepatide 10 mg · weight_tp · Results, Change in Body Weight, paragraph 1; Table 2
−19.5% (95% CI, −20.4 to −18.5) with a 10-mg dose
- tirzepatide 10 mg · ae_dc · Results, Participants; Table 4 (45 [7.1])
Treatment discontinuations due to adverse events were 4.3%, 7.1%, and 6.2% with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 2.6% with placebo.
- tirzepatide 10 mg · nausea · Table 4, adverse events in at least 5% of participants
Nausea 155 (24.6) 212 (33.3) 195 (31.0) 61 (9.5)
- tirzepatide 10 mg · vomiting · Table 4, adverse events in at least 5% of participants
Vomiting 52 (8.3) 68 (10.7) 77 (12.2) 11 (1.7)
- tirzepatide 10 mg · sae · Table 4
Serious adverse events 40 (6.3) 44 (6.9) 32 (5.1) 44 (6.8)
- tirzepatide 15 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Fig. 1B
−22.5% (95% CI, −23.3 to −21.7), a reduction of 23.6 kg (52.0 lb) with the 15-mg dose
- tirzepatide 15 mg · weight_tp · Results, Change in Body Weight, paragraph 1; Table 2
−20.9% (95% CI, −21.8 to −19.9) with a 15-mg dose
- tirzepatide 15 mg · ae_dc · Results, Participants; Table 4 (39 [6.2])
Treatment discontinuations due to adverse events were 4.3%, 7.1%, and 6.2% with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 2.6% with placebo.
- tirzepatide 15 mg · nausea · Table 4, adverse events in at least 5% of participants
Nausea 155 (24.6) 212 (33.3) 195 (31.0) 61 (9.5)
- tirzepatide 15 mg · vomiting · Table 4, adverse events in at least 5% of participants
Vomiting 52 (8.3) 68 (10.7) 77 (12.2) 11 (1.7)
- tirzepatide 15 mg · sae · Table 4
Serious adverse events 40 (6.3) 44 (6.9) 32 (5.1) 44 (6.8)
Related registry entries
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| SURMOUNT-1 Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | Obesity | Phase 3 | recruiting | 2026-02 → 2027-02 | 2539 | recruiting | NCT07481747 |
| SURMOUNT-1 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight | Obesity | Phase 3 | completed | 2019-12 → 2022-04 | 2539 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT04184622 |
Primary sources
- Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024.
- Eli Lilly and Company. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1) (SURMOUNT-1). ClinicalTrials.gov identifier NCT04184622. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT04184622
- ClinicalTrials.gov NCT07481747
How to cite this page
Medical Adviser's Group. Incretin Atlas: SURMOUNT-1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.